technetium-99 niacinamide polyethylene glycol bicyclic RGD peptide
Phase 3- Indications
- Lung cancer, Oesophageal cancer, Cancer
Company intelligence / Profile preview
Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd. is an active Chinese pharmaceutical company involved primarily in sponsoring and conducting clinical trials across a range of therapeutic areas including oncology, metabolic diseases, and CNS disorders. The company appears to function as a CRO or development partner for other pharmaceutical entities within China. No specific drug approvals or late-stage assets are publicly documented.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd..